Cabaletta Bio, Inc. (CABA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$116.6M
Cash & Equivalents
$42.6M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$485M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06154252 | RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic I... | PHASE3 | Recruiting | 74 |
| NCT06328777 | RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects W... | PHASE2 | Recruiting | 12 |
| NCT04422912 | A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T... | PHASE2 | Recruiting | 40 |
| NCT06359041 | RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | PHASE2 | Active Not Recruiting | 12 |
| NCT06121297 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic... | PHASE2 | Recruiting | 28 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-03 | 8-K | Cabaletta Bio, Inc. (CABA) (CIK 0001759138) - EX-99.2 | EDGAR |